Dan Manea Biography and Net Worth

SVP of Insulet

Mr. Manea has served as our Senior Vice President and Chief Human Resources Officer since May 2020. He has extensive cross-cultural, functional, and geographical experience. Prior to joining Insulet, he was at Novartis for 14 years where he served in various senior Human Resources positions at the global and regional level including Global Head of HR for Novartis Oncology. Most recently, he was the Country People & Organization Head for Novartis, U.S. Prior to joining Novartis, Mr. Manea held positions in HR at Eli Lilly across Europe, the U.S., and Middle East. He has broad expertise in talent acquisition, talent development, total rewards, and organizational design and strategic planning. Throughout his career, he has focused on building empowered, high-performing teams. Mr. Manea is a lifetime learner and appreciates the diversity of people’s strengths and talents to create strong global organizations. He is committed to helping people grow to reach their true potential. Mr. Manea is a medical doctor and practiced medicine for several years in his native Romania. He earned a Master of Business Administration from Washington State University and the Romanian Academy of Economic Studies.

What is Dan Manea's net worth?: The estimated net worth of Dan Manea is at least $1.21 million as of June 20th, 2023. Mr. Manea owns 4,522 shares of Insulet stock worth more than $1,205,475 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Manea may own. Learn More about Dan Manea's net worth.
How do I contact Dan Manea?: The corporate mailing address for Mr. Manea and other Insulet executives is 100 NAGOG PARK, ACTON MA, 01720. Insulet can also be reached via phone at (978) 600-7000 and via email at [email protected]. Learn More on Dan Manea's contact information.
Has Dan Manea been buying or selling shares of Insulet?: Dan Manea has not been actively trading shares of Insulet during the past quarter. Most recently, Dan Manea sold 175 shares of the business's stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $290.00, for a transaction totalling $50,750.00. Following the completion of the sale, the senior vice president now directly owns 4,522 shares of the company's stock, valued at $1,311,380. Learn More on Dan Manea's trading history.
Who are Insulet's active insiders?: Insulet's insider roster includes Charles Alpuche (COO), Eric Benjamin (SVP), Luciana Borio (Director), Bret Christensen (EVP), Sally Crawford (Director), John Fallon (Director), Mark Field (SVP and Chief Technology Officer), James Hollingshead (CEO), Dan Manea (SVP), Wayde McMillan (CFO), Shacey Petrovic (CEO), Timothy Scannell (Director), Prem Singh (SVP), and Michael Spears (SVP). Learn More on Insulet's active insiders.
Are insiders buying or selling shares of Insulet?: In the last twelve months, insiders at the medical instruments supplier sold shares 5 times. They sold a total of 25,540 shares worth more than $4,527,624.61. The most recent insider tranaction occured on June, 14th when SVP Mark N Field sold 1,500 shares worth more than $299,940.00. Insiders at Insulet own 0.5% of the company. Learn More about insider trades at Insulet.
Information on this page was last updated on 6/14/2024.

Dan Manea Insider Trading History at Insulet

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/20/2023	Sell	175	$290.00	$50,750.00	4,522
11/18/2022	Sell	200	$294.62	$58,924.00	3,158

Dan Manea Buying and Selling Activity at Insulet

Insulet Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Today's Range

Now: $266.58

$260.63

$267.05

50 Day Range

MA: $240.09

$227.79

$275.70

2 Week Range

Now: $266.58

$160.19

$279.40

Volume

504,270 shs

Average Volume

606,420 shs

Market Capitalization

$18.70 billion

P/E Ratio

45.65

Dividend Yield

N/A

Beta

1.22

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW